Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders:

NCT05136976 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire de Saint Etienne as lead sponsor.

NCT NCT05136976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05136976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders:
Lead sponsor
Centre Hospitalier Universitaire de Saint Etienne
Phase
Phase 3
Overall status
Recruiting
Start date
June 29, 2023
Completion date
December 31, 2028
Enrollment
90 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

anti-mag neuropathy